ABSTRACT
BACKGROUND: Transjugular intrahepatic portosystemic shunt is a treatment for complications of portal hypertension, such as bleeding gastroesophageal varices and refractory ascites. In this article we reveal our experiences with this treatment modality. MATERIAL AND METHOD: All patients who had a transjugular intrahepatic portosystemic shunt inserted in the period 2011 - 2021 at Oslo University Hospital Ullevål were studied retrospectively. The cumulative incidence of death was calculated with liver transplantation as a competing event. RESULTS: The procedure was technically successful in 62 of 64 patients. The average reduction of the pressure gradient between the inferior vena cava and the portal vein was 12.7 (standard deviation 5.0) mm Hg. One of 31 patients who underwent the procedure because of gastrointestinal bleeding experienced a new episode of bleeding, and 4 of 29 patients who underwent the procedure because of ascites needed a further one to two paracenteses. Two of 62 patients had complications directly related to the procedure in the form of liver abscess and portal vein thrombosis. Five of 62 patients developed symptoms of heart failure or fluid overload. After one, three and twelve months, 49 of 62 (79 %), 45 of 62 (73 %) and 38 of 62 (61 %) patients respectively were still alive. The procedure functioned as a 'bridge to liver transplantation' for eight patients with refractory ascites. INTERPRETATION: Transjugular intrahepatic portosystemic shunt is a useful treatment method for complications of portal hypertension.
Subject(s)
Esophageal and Gastric Varices , Hypertension, Portal , Portasystemic Shunt, Transjugular Intrahepatic , Ascites/etiology , Ascites/surgery , Esophageal and Gastric Varices/complications , Esophageal and Gastric Varices/surgery , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/surgery , Hemorrhage/etiology , Humans , Hypertension, Portal/complications , Hypertension, Portal/surgery , Portasystemic Shunt, Transjugular Intrahepatic/adverse effects , Portasystemic Shunt, Transjugular Intrahepatic/methods , Retrospective Studies , Treatment OutcomeABSTRACT
Purpose: Until recently, it has been believed that donating a kidney not represents any risk for development of cardiovascular disease. However, a recent Norwegian epidemiological study suggests that kidney donors have an increased long-term risk of cardiovascular mortality. The pathophysiological mechanisms linking reduced kidney function to cardiovascular disease are not known. Living kidney donors are screened for cardiovascular morbidity before unilateral nephrectomy, and are left with mildly reduced glomerular filtration rate (GFR) after donation. Therefore, they represent an unique model for investigating the pathogenesis linking reduced GFR to cardiovascular disease and cardiovascular remodelling. We present the study design of Cardiovascular rEmodelling in living kidNey donorS with reduced glomerular filtration rate (CENS), which is an investigator-initiated prospective observational study on living kidney donors. The hypothesis is that living kidney donors develop cardiovascular remodelling due to a reduction of GFR.Materials and methods: 60 living kidney donors and 60 age and sex matched healthy controls will be recruited. The controls will be evaluated to fulfil the Norwegian transplantation protocol for living kidney donors. Investigations will be performed at baseline and after 1, 3, 6 and 10 years in both groups. The investigations include cardiac magnetic resonance imaging, echocardiography, bone density scan, flow mediated dilatation, laser Doppler flowmetry, nailfold capillaroscopy, office blood pressure, 24-h ambulatory blood pressure, heart rate variability and investigation of microbiota and biomarkers for inflammation, cardiovascular risk and the calcium-phosphate metabolism.Conclusions: The present study seeks to provide new insight in the pathophysiological mechanisms linking reduced kidney function to cardiovascular disease. In addition, we aim to enlighten predictors of adverse cardiovascular outcome in living kidney donors. The study is registered at Clinical-Trials.gov (identifier: NCT03729557).
Subject(s)
Cardiovascular Diseases/physiopathology , Glomerular Filtration Rate , Kidney Diseases/physiopathology , Kidney Transplantation , Kidney/physiopathology , Living Donors , Nephrectomy/adverse effects , Vascular Remodeling , Ventricular Remodeling , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/etiology , Case-Control Studies , Humans , Kidney Diseases/diagnosis , Kidney Diseases/etiology , Longitudinal Studies , Norway , Prospective Studies , Research Design , Risk Assessment , Risk Factors , Time Factors , Treatment OutcomeSubject(s)
Cystitis/complications , Emphysema/complications , Pyelonephritis/complications , Urinary Tract Infections/etiology , Aged , Anti-Bacterial Agents/therapeutic use , Cystitis/drug therapy , Cystitis/microbiology , Cystitis/surgery , Emphysema/drug therapy , Emphysema/microbiology , Emphysema/surgery , Escherichia coli/isolation & purification , Escherichia coli Infections/drug therapy , Escherichia coli Infections/etiology , Escherichia coli Infections/microbiology , Escherichia coli Infections/surgery , Female , Gases , Humans , Middle Aged , Pyelonephritis/drug therapy , Pyelonephritis/microbiology , Pyelonephritis/surgery , Stents , Urinary Tract Infections/drug therapy , Urinary Tract Infections/microbiology , Urinary Tract Infections/surgeryABSTRACT
BACKGROUND AND PURPOSE: This study aimed to assess the effects of supervised exercise training (SET) after percutaneous transluminal angioplasty (PTA) compared with PTA alone on physical function, limb hemodynamics and health-related quality of life in patients with intermittent claudication. METHODS: Fifty patients who all underwent PTA for intermittent claudication were included in the study. Both groups received usual post-operative care. In addition, the intervention group performed two sessions of hospital-based SET and one home-based exercise session per week for 12 weeks after PTA. The control group did not receive any additional follow-up regarding exercise. The primary outcome was the result of a standardized 6-minute walk test. Secondary outcomes were the treadmill maximum walking distance, treadmill pain-free walking distance, ankle-brachial index, pulse volume recording on the leg and ultrasound scanning. Health-related quality of life was measured using the Short Form 36 and the Claudication Scale. RESULTS: All measures, except for the Short Form 36 domain of mental health, showed statistically significant positive changes from baseline to 3 months for both groups (p < 0.05). At 3 months, there was a trend towards better results for the intervention group compared with the control group. The median improvement from baseline to 3 months for the 6-minute walk test was 66 m for the intervention group and 45 m for the control group. For maximum walking distance, the median improvement was 251 m for the intervention group and 93 m for the control group. DISCUSSION: Supervised exercise training after endovascular treatment for patients with intermittent claudication led to greater positive changes after 3 months in the intervention group compared with the control group. The present study's trends of better results with SET after PTA add to the emerging existing evidence, which should encourage physiotherapy practice to offer SET for this patient group.
Subject(s)
Endovascular Procedures/methods , Exercise Therapy/methods , Exercise Tolerance/physiology , Intermittent Claudication/rehabilitation , Peripheral Arterial Disease/rehabilitation , Walking/physiology , Aged , Aged, 80 and over , Endovascular Procedures/adverse effects , Female , Follow-Up Studies , Humans , Intermittent Claudication/diagnostic imaging , Intermittent Claudication/therapy , Male , Middle Aged , Norway , Pain Measurement , Peripheral Arterial Disease/diagnostic imaging , Peripheral Arterial Disease/therapy , Postoperative Care/methods , Regional Blood Flow/physiology , Risk Assessment , Severity of Illness Index , Single-Blind Method , Statistics, Nonparametric , Time Factors , Treatment Outcome , Ultrasonography, DopplerABSTRACT
OBJECTIVES: The aim of the present study was to elucidate right ventricular (RV) function and structure in patients with chronic obstructive pulmonary disease (COPD) without pulmonary hypertension (PH). BACKGROUND: There is little knowledge of RV function and remodeling in COPD without PH. METHODS: Thirty-four controls and 98 patients with COPD were included. The study patients were divided into 2 groups by right heart catheterization: no PH (mean pulmonary artery pressure [mPAP] <25 mm Hg) and PH (mPAP ≥25 mm Hg). The echocardiographic tissue Doppler imaging variables of RV isovolumic acceleration, peak systolic strain, and RV myocardial performance index were measured at the basal free wall, and RV wall thickness and RV internal dimension were measured in the RV outflow tract. RESULTS: The increases in RV wall thickness and RV dimension were more evident when comparing controls with the no PH group (3.5 ± 0.5 mm to 5.5 ± 1.0 mm [p < 0.01] and 1.5 cm ± 0.2 to 2.0 ± 0.5 cm [p < 0.01]) than comparing the no PH group with the PH group (5.5 ± 1.0 mm to 6.6 ± 1.1 mm [p < 0.01] and 2.0 cm ± 0.5 to 2.1 ± 0.3 cm [p = NS]), respectively. Similarly, RV isovolumic acceleration, performance index, and strain deteriorated significantly when comparing controls with the no PH group and comparing the no PH group with the PH group (p < 0.01). Significant correlations were observed between mPAP and RV isovolumic acceleration, performance index, strain, and RV wall thickness (p < 0.01). RV impairment and increased RV wall thickness and RV dimensions were present even at slight elevations of mPAP (18 ± 3 mm Hg) in the no PH group. CONCLUSIONS: The present study showed that impaired RV systolic function, hypertrophy, and dilation were present even at a slight increase of mPAP, which indicates an early impact on RV function and structure in patients with COPD. RV isovolumic acceleration, performance index, and strain could detect subclinical disease and separate controls from those with no PH.